Karin Conde-Knape became the senior vice president of global drug discovery at Novo Nordisk a little over a year ago. Here, she's in charge of preliminary research withinin several therapy areas that are of interest to the pharmaceutical giant.
"If I had to be more specific, I would say it's our responsibility to discover new potential treatments in the disease areas that are relevant to Novo Nordisk," Conde-Knape says.
Already a subscriber? Log in.
Read the whole article
Get access for 14 days for free.
No credit card is needed, and you will not be automatically signed up for a paid subscription after the free trial.
- Access all locked articles
- Receive our daily newsletters
- Access our app